Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVOCATE phase 3 trial of avacopan in ANCA-associated vasculitis
2016-001121-14Phase 3Completed
- Sponsor
- ChemoCentryx
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by ChemoCentryx. Primary endpoint: Remission at Week 26. Started Dec 2016; status: completed.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2016-001121-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001121-14.